The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Open accessAbstract
Background Sotorasib is a specific, irreversible inhibitor of the GTPase protein, KRAS G12C. We compared the efficacy and safety of sotorasib with a standard-of-care treatment in patients with non-small-cell lung cancer (NSCLC) with the KRAS G12C mutation who had been previously treated with other anticancer drugs.Methods We conducted a randomised, open-label phase 3 trial at 148 centres in 22 countries. We recruited patients aged at least 18 years with KRAS G12C-mutated advanced NSCLC, who progressed after previous platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Key exclusion criteria included new or progressing untreated brain lesions or symptomatic brain lesions, previously identified oncogenic driver mutation other than KRAS G12C for which an approved therapy is available (eg EGFR or ALK), previous treatment with docetaxel (neoadjuvant or adjuvant docetaxel was allowed if the tumour did not progress within 6 months after the therapy was terminated), previous treatment with a direct KRAS G12C inhibitor, systemic anticancer therapy within 28 days of study day 1, and therapeutic or palliative radiation therapy within 2 weeks of treatment initiation. We randomly assigned (1:1) patients to oral sotorasib (960 mg once daily) or intravenous docetaxel (75 mg/m 2 once every 3 weeks) in an open-label manner using interactive response technology. Randomisation was stratified by number of previous lines of therapy in advanced disease (1 vs 2 vs >2), ethnicity (Asian vs non-Asian), and history of CNS metastases (present or absent). Treatment continued until an independent central confirmation of disease progression, intolerance, initiation of another anticancer therapy, withdrawal of consent, or death, whichever occurred first. The primary endpoint was progression-free survival, which was assessed by a blinded, independent central review in the intention-to-treat population. Safety was assessed in all treated patients. This trial is registered at ClinicalTrials.gov, NCT04303780, and is active but no longer recruiting.Findings Between June 4, 2020, and April 26, 2021, 345 patients were randomly assigned to receive sotorasib (n=171 [50%]) or docetaxel (n=174 [50%]). 169 (99%) patients in the sotorasib group and 151 (87%) in the docetaxel group received at least one dose. After a median follow-up of 17·7 months (IQR 16·4-20·1), the study met its primary endpoint of a statistically significant increase in the progression-free survival for sotorasib, compared with docetaxel (median progression-free survival 5·6 months [95% CI 4·3-7·8] vs 4·5 months [3·0-5·7]; hazard ratio 0·66 [0·51-0·86]; p=0·0017). Sotorasib was well tolerated, with fewer grade 3 or worse (n=56 [33%] vs n=61 [40%]) and serious treatment-related adverse events compared with docetaxel (n=18 [11%] vs n=34 [23%]). For sotorasib, the most common treatment-related adverse events of grade 3 or worse were diarrhoea (n= 20 [12%]), alanine aminotransferase increase (n=13 [8%]), and aspartate aminotransferase increase (n=9 [5%]). For docetaxel, the most common treatment-related adverse events of grade 3 or worse were neutropenia (n=13 [9%]), fatigue (n=9 [6%]), and febrile neutropenia (n=8 [5%]).Interpretation Sotorasib significantly increased progression-free survival and had a more favourable safety profile, compared with docetaxel, in patients with advanced NSCLC with the KRAS G12C mutation and who had been previously treated with other anticancer drugs.Funding Amgen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials of multiple KRASG12C inhibitors have shown promising efficacy in advanced, previously treated non–small cell lung cancer (NSCLC), leading to United States Food and Drug Administration (FDA) accelerated approval of two of these therapies (adagrasib and sotorasib) and many others being investigated in this setting (9–17).”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [15]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)11,23–25.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“while median overall survival was not improved with sotorasib compared with docetaxel (10.6 vs. 11.3 months; HR, 1.01) [25]”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“In the randomized phase III CodeBreaK 200 trial, sotorasib significantly improved progression-free survival compared with docetaxel in previously treated KRAS G12C-mutant NSCLC (median PFS, 5.6 vs. 4.5 months; HR, 0.66).”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [25]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, some patients selected for these trials may have preexisting multidrug resistance (9, 37, 74), which could contribute to treatment failure.”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [74]
Experimental — accuracy not yet measuredIn the citing paper
“Despite this success, disease progression occurs in many patients4,5,7, with development of resistance to KRASG12Ci recapitulated in preclinical studies9–11.”
From Co-targeting SOS1 enhances the antitumor effects of KRASG12C inhibitors by addressing intrinsic and acquired resistance (2024) · cites this paper as [5]
In the citing paper
“Multiple mechanisms of intrinsic and acquired resistance (10,12,13), have been identified; hence, drug combinations will likely be needed to maximize the clinical efficacy of G12Cis (and probably other, emerging KRAS inhibitors) in NSCLC and other diseases.”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Self-citationThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationFossella, F. V., DeVore, R. F., Kerr, R. N., Crawford, J., Natale, R. R., Dunphy, F., Kalman, L. A., Miller, V. A., Lee, J. S., Moore, M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.12.2354 · Cited by 1,360
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951
Self-citationFirst-Line Immunotherapy for Non–Small-Cell Lung Cancer
Reck, M., Remón, J., & Hellmann, M. D. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01497 · Cited by 909
Research works printed but not linked: 1
- Awad, 2022, Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): safety and efficacy data from the global expanded access program (EAP), Ann Oncol, 33, S448
Cited by
Sorted by citations
Items 301–400 of 619
Carlisle, J. W., Pentz, R. D., & Ramalingam, S. S. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.08.023 · Cited by 4
Self-citationHeynemann, S., Lipworth, W. L., McLachlan, S., Philip, J. A. M., John, T., & Kerridge, I. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.07.004 · Cited by 4
Engineered protein circuits for cancer therapyPreprint
Lu, A. C., Moeller, L., Moore, S., Ho, K., Tobin, V., Qiang, A., Zhang, E., Li, Z., Wang, M., Xia, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.16.647665 · Cited by 5
Kasper, S., & Sebastian, M. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2025.0002 · Cited by 3
EGFR blockade confers sensitivity to pan-RAS inhibitors in KRAS-mutated cancers
Han, J., Yu, B., Jing, J., He, X., Hua, Y., & Xu, G. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01075-4 · Cited by 3
Mechanisms and current advances in treating KRAS-mutated lung cancer
Chao, C. H.-Y., & Di, Y. P. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.08.001 · Cited by 6
Tirpe, A., Nutu, A. M., Busuioc, C. I., Pop, O. L., & Berindan‐Neagoe, I. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1677471 · Cited by 5
Pattern of brain metastases and survival in lung adenocarcinoma with KRAS or EFGR mutation
Faehling, M., Fallscheer, S., Schmiederer, J., Sträter, J., Christopoulos, P., Lengerke, C., & Seifarth, H. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108803 · Cited by 3
Riedel, R. F., Ruge, L., Verheyen, M., John, F., Scharpenseel, H., Nogová, L., Michels, S. Y. F., Fischer, R. N., Eisert, A., Jakob, C. E. M., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100925 · Cited by 3
Self-citationZheng, Y., Su, C., Pan, J., Wang, Y., Zhao, M., Zhang, M., Yan, P., Liu, N., & Sun, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1663502 · Cited by 4
Self-citationIdentifying targeted therapies for CBFA2T3::GLIS2 acute myeloid leukemia
Gonzales, F., Schneider, C., Alexe, G., Lin, S., Khalid, D., Alvarez, M., Basanthakumar, A. T., Ellegast, J. M., Merickel, L. A., Salhotra, S., et al. (2026) · Leukemia · doi:10.1038/s41375-025-02845-7 · Cited by 3
Advances on drug therapy for KRAS-mutant non-small-cell lung cancer
Tian, T., & Li, W. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102668 · Cited by 4
Lv, Y., Zhao, Z., Di, W., Liu, L., Chen, Y., Wei, S., Ji, Y., & Zhong, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105150 · Cited by 3
Self-citationWu, S.-G., & Chao-Chi, H. (2026) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2026.02.009 · Cited by 3
Olmo-González, D., Zhou, M., Oliveira, N. G., Zhou, F., Yan, F., González, J., València-Clua, K., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Giménez-Capitán, A. A., et al. (2026) · Cell Death Discovery · doi:10.1038/s41420-026-02998-z · Cited by 3
Systematic and precise interventions for KRAS-mutant cancers
Liang, J., Wu, J., Zhang, Y., Wang, H., Zheng, Y., & He, Q. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00763-7 · Cited by 4
Lopez, J. S., Harrington, K. J., Im, S., Lee, K., Postel-Vinay, S. C., Thomas, J. S., Lukashchuk, N., Willis, S. E., Irurzun‐Arana, I., Webb, B., et al. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03408-y · Cited by 3
Waldron, N. R., Silva, D. D., Westaby, D., Jiménez‐Vacas, J. M., Taylor, J., & Sharp, A. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03441-x · Cited by 3
Hanibuchi, M., Ogino, H., Sato, S., & Nishioka, Y. (2024) · The Journal of Medical Investigation · doi:10.2152/jmi.71.9 · Cited by 3
Jiang, N., Han, Y., Wang, S., & Li, N. (2024) · BMC Medicine · doi:10.1186/s12916-024-03414-y · Cited by 3
Jing, Y., Cheng, R., Zeng, H., Huang, Q., He, D., Sun, J., Tian, P., & Li, Y. (2024) · International Journal of General Medicine · doi:10.2147/ijgm.s484435 · Cited by 3
The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer
Zhao, X., Zheng, Y., Wang, Y., Zhang, M., Dong, Z., Liu, Y., & Sun, M. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s484209 · Cited by 4
Self-citationHepatobiliary Adverse Events Associated With the KRAS p.G12C Inhibitor Sotorasib
Frey, C. (2025) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.70104 · Cited by 3
Gene mutation, clinical characteristics and pathology in resectable lung adenocarcinoma
Zou, J. P., Han, W., Hu, Y. T., Zeng, C., Li, J., Lei, W., Cao, J., Fei, Q., Shao, M., Yi, J., et al. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03680-x · Cited by 4
Dong, P., Ni, J., Zheng, X., Wang, M., Yang, M., & Han, H. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177428 · Cited by 3
Sotorasib’s Accelerated Approval
Ratain, M. J., & Kesselheim, A. S. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.0039 · Cited by 3
Nakanishi, K., Ogino, H., Murakami, K., Saijo, Y., Naito, N., Matsumoto, R., Morita, Y., Tsukazaki, Y., Ozaki, R., Yabuki, Y., et al. (2025) · International Cancer Conference Journal · doi:10.1007/s13691-025-00780-z · Cited by 3
Wislez, M., Giannopoulou, A., Borget, I., Lindsay, C. R., Rothschild, S. I., Vincent, B., Milce, J., Sultan, I., Stollenwerk, B., & Pless, M. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2535225 · Cited by 3
Self-citationAdagrasib for KRASG12C mutated advanced non-small-cell lung cancer
Smit, E. F., & Dingemans, A. C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01149-3 · Cited by 3
Self-citationWu, L., Jiang, W., Liu, Z., Zhang, Y., Qian, J., Liu, Y., Huang, Y.-Y., Li, K., Li, Z., Ma, G.-W., et al. (2023) · Discover Oncology · doi:10.1007/s12672-023-00698-z · Cited by 4
Hamilton, G., Stickler, S., & Rath, B. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00178 · Cited by 3
McIntyre, S. M. H., Preston, W. A., Walch, H. S., Sharib, J. M., Kundra, R., Sigel, C., Lidsky, M. E., Allen, P. J., Morse, M. A., Chen, W., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00534 · Cited by 5
STUB1 promotes the degradation of HSPB1 and induces ferroptosis in lung cancer cells
Tieliwaerdi, A., Aini, A., Amuti, M., Aierken, Y., Nijiati, M., & Luo, B. (2024) · Environmental Toxicology · doi:10.1002/tox.24296 · Cited by 3
Giglio, A. D., Zacchini, F., Venturi, G., Federico, A. D., Parisi, C., Dall’Olio, F. G., Ricciotti, I., Favorito, V., Gagliano, A., de Biase, D., et al. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100161 · Cited by 3
Jayakrishnan, R., Kwiatkowski, D. J., Rose, M. G., & Nassar, A. H. (2024) · The Oncologist · doi:10.1093/oncolo/oyae091 · Cited by 3
Zhang, Z. (2024) · American Journal of Cancer Research · doi:10.62347/xebr7848 · Cited by 3
Desai, A. P., & Dimou, A. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.013 · Cited by 3
Sotorasib in KRASG12C mutated lung cancer – Authors' reply
Paz-Ares, L. G., Mehta, B., Wang, Y., Obiozor, C. C., Waterhouse, D. M., & Langen, A. J. D. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02036-6 · Cited by 3
Self-citationSotorasib versus docetaxel: evidence supporting CodeBreaK 200
Paz-Ares, L. G., Mehta, B., Wang, Y., Waterhouse, D. M., & Langen, A. J. D. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00388-7 · Cited by 3
Self-citationMeraz, I. M., Wu, S., Xu, Y., Gao, L., Feng, M., Ren, C., Song, R., Zhang, R., Wang, Q., Xi, Y., et al. (2025) · eLife · doi:10.7554/elife.106875.1 · Cited by 3
Shi, Y., Bi, M., Li, Q., Wang, G., Chen, J., Li, M., Shi, J., Mei, J., Ji, Y., Xia, Q., et al. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.01.001 · Cited by 2
The uncharacterized transcript KIAA0930 confers a cachexic phenotype on cancer cells
Yamakawa, T., Zhang, G., Najjar, L. B., Li, C., & Itakura, K. (2023) · Oncotarget · doi:10.18632/oncotarget.28476 · Cited by 3
Tackling KRASG12C-mutated non-small-cell lung cancer: iteration and exploration
Luo, J., & Villaruz, L. C. (2024) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(24)00116-4 · Cited by 2
KRAS inhibitors in drug resistance and potential for combination therapy
Rathod, L. S., Sakle, N. S., & Mokale, S. N. (2024) · Tumori Journal · doi:10.1177/03008916241289206 · Cited by 3
Decoster, L., Camidge, D. R., Fletcher, J. A., Addeo, A., Greystoke, A., Kantilal, K., Bigay-Game, L., Kanesvaran, R., & Gomes, F. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108087 · Cited by 2
Bhatt, A., Yone, N., Lalla, M., Jeon, H., & Cheng, H. (2025) · Cancers · doi:10.3390/cancers17121950 · Cited by 3
Chemometric modelling of anticancer drugs using CatBoost regression and graphical derivatives
Huang, Y., Hanif, M. F., Maqsood, E., & Rehman, M. (2025) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2025.105551 · Cited by 2
Yi, C., Zhang, H., Guo, Q., Lu, L., Gao, C. F., Zhao, Y.-L., Su, Y., & Lü, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1642999 · Cited by 2
Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer
Zhu, L., Jia, X., Xu, L., Chen, L., Fu, X., Yan, H., Ai, B., & Peng, S. (2025) · iScience · doi:10.1016/j.isci.2025.114429 · Cited by 2
Gang, X., Sun, Y., Hao, J., Zhao, S., Wang, Y., Yang, X., Li, H., & Zhao, M. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.108930 · Cited by 2
Self-citationGalvão, J., Bezerra, A. F. S. P., Garcia, F. A. D. O., Vieira, A. G. S., da Silva, E. C. A., Lengert, A. V. H., Reis, R. M., Lopes, L., Evangelista, A., & Pinto, M. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1689022 · Cited by 2
Guan, S., Huangfu, J., Zhu, X., Ge, Y., Ding, Y., Chen, T., Zhang, Y., Yang, T., Liu, H., Zhang, L., et al. (2026) · Cancer Management and Research · doi:10.2147/cmar.s580857 · Cited by 3
From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC
Canaslan, K., Başbınar, Y., & Öztop, İ. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105344 · Cited by 2
KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians
Remón, J., Cava, G. L., Borgeaud, M., Saw, S. P. L., Hendriks, L. E. L., & Ricciuti, B. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103144 · Cited by 3
Lin, W., Chen, Q., Yang, Y., Gao, Y., & He, J. (2026) · Experimental Hematology and Oncology · doi:10.1186/s40164-026-00797-x · Cited by 2
Targeting KRAS for cancer therapy
Jia, J., Liu, R., Adamide, T. A., Fernandez, I. E., & Stathopoulos, G. T. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70546 · Cited by 3
Song, Z., Li, X., Lin, R., Shi, H., Yuan, Y., Liu, Y., Luo, Y., Lv, T., Zhang, Y., Zhu, L., et al. (2026) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(26)00142-6 · Cited by 2
Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers
O’Leary, C., Murphy, G., Yeung, Y., Tang, M., Jain, V. K. S., & O’Leary, C. G. (2023) · Cancers · doi:10.3390/cancers15235582 · Cited by 2
Xu, J., & Wang, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1285593 · Cited by 2
Lyu, M., Luo, L., Zhou, L. H., Feng, X., Yang, J. B., Xu, Z., Sun, X., Bao, Z., Wang, X., Gao, B., et al. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03264-x · Cited by 2
Stratton, N. C., & Thompson, J. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100661 · Cited by 2
Li, J. J., Wu, X. J., Farzin, M., Bray, V., Williamson, J., Pal, A., Yip, P. Y., Hagelamin, A., Ding, P., Nindra, U., et al. (2024) · Pathology · doi:10.1016/j.pathol.2024.04.002 · Cited by 2
Aptekar, J. W., Jain, R., Korytowsky, B., Shafquat, A., Hendershot, J. M., Talwai, A., Itzkovich, Y., & Padda, S. K. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107854 · Cited by 2
Jiang, J., Berry, M. F., Lui, N. S., Liou, D. Z., Trope, W., Backhus, L. M., & Shrager, J. B. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-165 · Cited by 2
First Reported Case of Pure Red Cell Aplasia Related to Sotorasib
Itogawa, K., Saito, T., Nakata, Y., Amari, H., Tahara, H., Yoshino, N., Maeda, Y. K., Nomura, M., Shiihara, J., Nagai, Y., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3961-24 · Cited by 2
Metastatic colon cancer: clinical practice guideline update in 2024
Fedyanin, M. Y., Gladkov, O. A., Gordeyev, S. S., Карачун, А. М., Козлов, Н. А., Mamedli, Z. Z., Rykov, I. V., Tryakin, A. A., Цуканов, А. С., & Черных, М. В. (2024) · Surgery and Oncology · doi:10.17650/2949-5857-2024-14-4-31-42 · Cited by 2
Melosky, B. L., Juergens, R. A., Banerji, S. O., Sacher, A. G., Wheatley‐Price, P., Snow, S. L., Tsao, M., Leighl, N. B., Martins, I., Cheema, P. K., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241308784 · Cited by 2
Treating KRAS G12C lung cancer: therapeutic potential of investigation drugs in early clinical study
Wilson, K., Banda, J. S. F., Raza, F., Bukkapatnam, S., Gangane, S., & Massarelli, E. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2511175 · Cited by 2
Wen, J., Dong, Y., Chen, T., Wu, J., Zhong, Y., Xu, L., Si, H., Huang, S., Hou, L., She, Y., et al. (2025) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2025.04.040 · Cited by 2
Case Report: Case series: association between blood concentration and side effects of sotorasib
Shigaki, R., Yoshida, R., Yagita, A., Nagasue, K., Naraoka, T., Nitanai, K., Yanada, H., Tenma, T., Kida, R., Umekage, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1269991 · Cited by 2
Sotorasib in KRASG12C mutated lung cancer
Olivier, T., & Prasad, V. K. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02035-4 · Cited by 2
It is time to rethink randomized clinical trial approaches
Stewart, D. J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae172 · Cited by 2
Özakıncı, H., Desai, B., Kalos, D., Chen, D., Henry, M., Solanki, H. S., Boyle, T. A., Bittar, H. E. T., Nazario, G. S., Haura, E. B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.17.628751 · Cited by 2
Advancements in non-small cell lung cancer treatment: from early to advanced stages
Płużański, A., & Piórek, A. (2024) · Oncology in Clinical Practice · doi:10.5603/ocp.100477 · Cited by 1
Tamayo, N. A., Wurz, R. P., & Lanman, B. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00001-2 · Cited by 1
KRAS G12C Inhibitors: New Drugs, A New Hope
Singhal, S., Schokrpur, S., Gandara, D. R., & Riess, J. W. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.09.1383 · Cited by 1
Huijs, J. W. J., Bortolot, M., Berghoff, A. S., Brastianos, P. K., Degens, J. H. R. J., Ruysscher, D. D., Compter, A., & Hendriks, L. E. L. (2025) · Neuro-Oncology Practice · doi:10.1093/nop/npaf018 · Cited by 2
Missed Opportunity for Sotorasib Dose Optimization
Strohbehn, G. W., Feldman, J., Popat, S., & Ratain, M. J. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02468 · Cited by 1
Kandula, J. S., Parmar, K., Priyadharshni, A. R., Kumar, A., & Radhakrishnanand, P. (2025) · Chirality · doi:10.1002/chir.70037 · Cited by 1
Zhu, J., Xun, X., Liu, J., Su, B., Li, Y., Chen, H., & Huang, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1614283 · Cited by 1
Molecular Markers in the Era of Precision Care in Lung Cancer
Paranjpe, I., Salter, A. I., Chen, K. S.-M., & Das, M. S. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2649-9199 · Cited by 2
Profiling opnurasib (JDQ-443) for the treatment of non-small cell lung cancer (NSCLC)
Herrmann, A. C., Azenkot, T., Hilburn, V., & Bazhenova, L. A. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2536352 · Cited by 1
Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance
Luo, X., Zhou, F., Tang, Y., Liu, X., Xiao, R., Gu, M., Bai, J., Jiang, D., Yang, G., You, L., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003776 · Cited by 2
Wei, G., Tang, J., Wang, H., & Zhang, D. (2025) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s531038 · Cited by 1
Hu, H., Gao, F., Lin, M., Liu, R., Chi, J., & Guo, J. (2025) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1869_23 · Cited by 1
Emerging Targets in Non-Small Cell Lung Cancer
Wang, J., Biglow, L. R., & Baumgart, M. A. (2025) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s511767 · Cited by 1
KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC
Tubita, A., Fancelli, S., Anela, L., Petroni, G., Caliman, E., Mazzoni, F., Scolari, F., Napolitano, B., Menicacci, B., Comin, C., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1654491 · Cited by 1
Davoudi, Z., Dexheimer, T. S., Coussens, N. P., Silvers, T. E., Fox, R. G., Kemp, S. B., Juneja, P., Morris, J., Hollingshead, M. G., Takebe, N., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0582 · Cited by 2
Gando, Y., & Yasu, T. (2025) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2025.01077 · Cited by 1
The importance and utility of post market drug safety monitoring in cancer therapy
Levêque, D. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2575099 · Cited by 1
The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations
Ballesteros-González, I., Hernández-Navas, I., Brehey, O., Lechuga, C. G., Salmón, M., Scotece, M., Velasco-Vicente, R., Flores-Gómez, A. A., Cebriá, A., Simón-Carrasco, L., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00326-z · Cited by 1
Self-citationCabon, J., Lerouge, D., Thureau, S., Balosso, J., Guigo, M., Gervais, R., Dubos, C., Dô, P., Demontrond, P., Curcio, H., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1675825 · Cited by 1
He, D., Zhu, Y., Zhong, J., Cai, H., Li, Y., Zhuang, W., He, Y., Xu, Y., Fan, L., Fei, K., et al. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.11.003 · Cited by 2
M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors
Takamori, S., Haratake, N., Bhattacharya, A., Ozawa, H., Shigeta, K., Onishi, M., Nonaka, K., Komiya, T., Komatsuda, H., Takenaka, T., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03934-2 · Cited by 1
Carvalho, D., Pinto, S. F. T., & Sarmento, B. F. C. C. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.12.018 · Cited by 2
Joshi, K., Suvilesh, K. N., Natesh, N. S., Manjunath, Y., Coberly, J., Schlink, S., Kunin, J. R., Prather, R. S., Whitworth, K. M., Nelson, B., et al. (2025) · Lab Animal · doi:10.1038/s41684-025-01650-0 · Cited by 1
Ryu, S., Baig, M. H., Panwar, U., Dong, J.-J., Jo, Y. S., Kim, C. J., Nale, S. D., Park, J., Ha, J., Moon, B., et al. (2026) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.111437 · Cited by 1
Karim, N., Waterhouse, D. M., Jones, S., & Stollenwerk, B. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2604968 · Cited by 1
Self-citationKRAS mutated lung adenocarcinoma responds to pan-ERBB and Aurora kinase inhibitors
Uras, I. Z., Trkulja, M. V., Salama, A. K. A. A., Horvath, J., Asnani, K., Trenk, C., Kubicek, S., Bilban, M., Moll, H. P., & Casanova, E. (2026) · npj Precision Oncology · doi:10.1038/s41698-025-01242-8 · Cited by 1
Wang, X.-D., Lin, J.-H., & Hu, M.-H. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.111181 · Cited by 1
Metadata
- Authors
- de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., Yoneshima, Y., Kim, S.-W., Linardou, H., Novello, S., van der Wekken, A. J., Chen, Y., Peters, S., Felip, E., Solomon, B. J., Ramalingam, S. S., Dooms, C., Lindsay, C. R., Ferreira, C. G., Blais, N., Obiozor, C. C., Wang, Y., Mehta, B., Varrieur, T., Ngarmchamnanrith, G., Stollenwerk, B., Waterhouse, D., & Paz-Ares, L.
- Affiliations
- Sarah Cannon (US)
- Erasmus MC (NL)
- Henry Dunant Hospital (GR)
- Kantonsspital Winterthur (CH)
- University Hospital Cologne (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Kyushu University Hospital (JP)
- Asan Medical Center (KR)
- Metropolitan Hospital (GR)
- Ospedale San Luigi Gonzaga (IT)
- Centre Hospitalier Universitaire Vaudois (CH)
- Vall d'Hebron Hospital Universitari (ES)
- Peter MacCallum Cancer Centre (AU)
- Emory University (US)
- KU Leuven (BE)
- University of Manchester (GB)
- Centre Hospitalier de l’Université de Montréal (CA)
- Amgen (United States) (US)
- Amgen (Switzerland) (CH)
- Oncology Hematology Care (US)
- Universidad Complutense de Madrid (ES)
- Corresponding author
- Paz-Ares, Luis
- ORCID
- Johnson, Melissa L
- Dingemans, Anne-Marie C
- Mountzios, Giannis
- Pless, Miklos
- Wolf, Jürgen
- Skoulidis, Ferdinandos
- Yoneshima, Yasuto
- Kim, Sang-We
- Linardou, Helena
- Novello, Silvia
- Chen, Yuanbin
- Peters, Solange
- Felip, Enriqueta
- Solomon, Benjamin J
- Ramalingam, Suresh S.
- Dooms, Christophe
- Lindsay, Colin R
- Ferreira, Carlos Gil
- Blais, Normand
- Wang, Yang
- Stollenwerk, Björn
- Waterhouse, David
- Paz-Ares, Luis
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-03
- Volume
- 401
- Issue
- 10378
- Pages
- 733-746
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4319337483
- Cited by
- 619
- References
- 29
- Citations by year
- 2026: 146 · 2025: 196 · 2024: 196 · 2023: 81
- FWCI
- 113.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- HAL (submittedVersion)
- IRIS (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- SERVAL (Université de Lausanne) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Amgen
- Amgen Inc San Francisco
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- sotorasib, docetaxel, KRAS G12C mutation, non-small cell lung cancer, KRAS inhibitors, progression-free survival, second-line therapy, previously treated advanced NSCLC, central nervous system metastasis, treatment safety, oral versus intravenous administration, head-to-head comparison
- MeSH terms
- Docetaxel, Adolescent, Adult, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Piperazines, Pyridines, Pyrimidines, Proto-Oncogene Proteins p21(ras), Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
